Dabigatran Etexilate CAS 211915-06-9 CAS NO.211915-06-9
- FOB Price: USD: 30.00-50.00 /Gram Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,
- Available Specifications:
99%(1-9)Gram99%(10-50)Gram
- Product Details
Keywords
- 211915-06-9
- Dabigatran etexilate
- Novel synthetic direct thrombin inhibitor
Quick Details
- ProName: Dabigatran Etexilate CAS 211915-06-9
- CasNo: 211915-06-9
- Molecular Formula: C34H41N7O5
- Appearance: White crystalline powder
- Application: Novel synthetic direct thrombin inhibi...
- DeliveryTime: Within 3 workdays after payment
- PackAge: 1kg/BAG,25kg/DRUM,according to custom...
- Port: China main port
- ProductionCapacity: 10000 Metric Ton/Month
- Purity: 99%
- Storage: Cool
- Transportation: Air, sea, land transport
- LimitNum: 1 Gram
- Related Substances: 0
- Residue on Ignition: <0.5
- Heavy Metal: <0.003%
- Valid Period: 2 years
Superiority
Details
Product name |
Dabigatran Etexilate |
CAS NO. | 211915-06-9 |
Synonyms |
Dabigatran Etexilate |
Category | Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals. |
Purity | 99% Dabigatran Etexilate |
Appearance |
Dabigatran Etexilate powder |
Dabigatran Etexilate is an oral anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications and in some cases it offers an alternative to warfarin as the preferred orally administered anticoagulant ("blood thinner") since it does not require blood tests for international normalized ratio (INR) monitoring while offering similar results in terms of efficacy.
Dabigatran is used to prevent strokes in those with atrial fibrillation not caused by heart valve issues, as well as deep vein thrombosis and pulmonary embolism in persons who have been treated for 5–10 days with parenteral anticoagulant (usually low molecular weight heparin), and to prevent deep vein thrombosis and pulmonary embolism in some circumstances.
Dabigatran (Pradaxa, Prazaxa) is an anticoagulant medication that can be taken by mouth. It is being studied for various uses and in some cases is an alternative to warfarin, since it does not have to be monitored by blood tests, but offers similar results in terms of efficacy. It is in the class of a direct thrombin inhibitor.
It appears to be as effective as warfarin in preventing nonhemorrhagic strokes and embolic events in those with atrial fibrillation not due to valve problems.